Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

19.96 -0.48 (-2.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now
Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors. 
Via The Motley Fool
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders
Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven... 
Via Benzinga
72 Biggest Movers From Yesterday
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN... 
Via Benzinga
Topics Initial Public Offering
Analyst Ratings For Intellia Therapeutics
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA 
Via Benzinga
'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond
Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP). She doesn't own the stock, but she owns... 
Via Benzinga
Why Intellia Therapeutics Was a Winner on Wednesday
The company is about to fatten its coffers significantly. 
Via The Motley Fool
In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC
Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body. What Happened: On Monday,... 
Via Benzinga
Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar
Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia. 
Via InvestorPlace
Why Gene Editing Stocks Are Trading Higher Again Today
Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Dare Bioscience (NASDAQ:DARE) stock moved upwards by 26.82% to $2.08 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume... 
Via Benzinga
51 Stocks Moving In Wednesday's Mid-Day Session
Gainers Cuentas Inc. (NASDAQ: CUEN) shares jumped 176.6% to $7.69. The stock spiked following a press release saying "WaveMax to Implement the World's First Shared Wifi6... 
Via Benzinga
Unusual Options Activity Insight: Intellia Therapeutics
Shares of Intellia Therapeutics (NASDAQ:NTLA) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved up to $183.36. Sentiment... 
Via Benzinga
Stocks That Hit 52-Week Highs On Wednesday
This morning 132 companies reached new 52-week highs. Noteworthy Mentions: The largest company by market cap to break to a new 52-week high was NVIDIA (NASDAQ:NVDA... 
Via Benzinga
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Intellia Therapeutics Stock Moves Higher After Capital Raise Of $600M Issued At $145/Share
Intellia Therapeutics Inc (NASDAQ: NTLA) has priced a previously announced public offering at $145 per share, representing a discount of 4.4% from the last close... 
Via Benzinga
Can Intellia Therapeutics Turn Exciting Trial Results into Profits?
New proof-of-concept results are a big deal for the medical community, but what about for your portfolio? 
Via The Motley Fool
58 Biggest Movers From Yesterday
Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly amid increased attention from retail investors.... 
Via Benzinga
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust ... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Barclays raised the price target for Skyworks Solutions, Inc. (NASDAQ: 
Via Benzinga
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
Via FinancialNewsMedia
22 Stocks Moving in Tuesday's Pre-Market Session
Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday. Marin Software Incorporated (NASDAQ: MRIN) rose 36.8% to... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... 
Via Benzinga
Intellia Seeks To Raise $400M Via Equity
Intellia Therapeutics Inc (NASDAQ: NTLA) commenced an underwritten public offering of $400 million shares of its common stock. Underwriters have an option to... 
Via Benzinga
Intellia Therapeutics Analyst Doubles Price Target: What You Need To Know
An SVB Leerink genetic medicine analyst is bullish on shares of Intellia Therapeutics, Inc. (NASDAQ: 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.49% to 34,266.49 while the NASDAQ rose 0.72% to 14,463.26. The S&P also rose, gaining 0.05% to 4,283.04. The U.S. has... 
Via Benzinga
Topics Stocks
Intellia Makes a Splash, Bringing Other CRISPR Stocks Along for the Ride
Intellia's recent press release reveals first-of-its-kind clinical results for genome editing technology, leading NTLA stock skyward. 
Via InvestorPlace
Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money
Find out why these stocks are climbing higher. 
Via The Motley Fool
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Intellia Therapeutics (NASDAQ:NTLA 
Via Benzinga
Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump
Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0.01% to 4,280.50. The U.S. has the... 
Via Benzinga
Topics Stocks
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.